Organization:National Center for Advancing Translational Sciences

From HandWiki
Short description: An NIH agency of the US Department of Health and Human Services
National Center for Advancing Translational Sciences (NCATS)
National Center for Advancing Translational Sciences logo.png
AbbreviationNCATS
FormationDecember 23, 2011
TypeU.S. government agency
Legal statusActive
HeadquartersBethesda, Maryland, US
Director
Joni L. Rutter
Parent organization
National Institutes of Health
AffiliationsUnited States Public Health Service
Websitencats.nih.gov

The National Center for Advancing Translational Sciences (NCATS) was established on December 23, 2011[1] and is located in Bethesda, Maryland. NCATS is one of 27 institutes and centers of the U.S. National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services. The mission of NCATS is to transform scientific discoveries into new treatments and cures for disease that can be delivered faster to patients. The budget provided to NCATS for fiscal year 2018 is $557,373,000.[2]

History

NCATS was created on December 23, 2011 by the Consolidated Appropriations Act, 2012.[3]

The center was created from a number of existing NIH programs:[4]

Directors

Past directors 2011 – present[7]

Portrait Director Took office Left office
Thomas Insel NIMH 2011.JPG Thomas R. Insel (acting) December 23, 2011 September 22, 2012
NCATS Director Christopher P. Austin.jpg Christopher P. Austin September 23, 2012 April 15, 2021
NCATS Director Joni L. Rutter.jpg Joni L. Rutter April 16, 2021 Present

Divisions

NCATS is organized into a number of divisions:

  • Division of Clinical Innovation
  • Division of Pre-Clinical Innovation
  • Office of Administrative Management
  • Office of Grants Management and Scientific Review
  • Office of Rare Diseases Research: Oversees the Rare Diseases Clinical Research Network and Genetic and Rare Diseases Information Center (GARD)[8]
  • Office of Strategic Alliances: Works with businesses in the biotech and pharmaceutical industry to speed the development of new drugs[8]

Programs and initiatives

Overview

The stated goal of NCATS is to promote research in both existing and new areas of medicine and science, in order to promote public health and to overcome high failure rates in clinical trials.[9][10] To accomplish this, NCATS supports 31 programs and initiatives that relate to translational research and improving the speed of therapeutic development.[11] The 31 programs and initiatives involve a range of STEM-related fields including biology, biochemistry, chemistry, bioengineering, virology, genetics, and data science.[12] Within the realm of translational science, issues that NCATS is particularly focused on addressing using its programs, initiatives, and partnerships include increasing the success and de-risking the costs associated with therapeutic development, incentivizing more collaborative work, and addressing data transparency issues.[13]

COVID response

During the COVID-19 pandemic, NCATS launched an open data initiative to promote collaborative sharing of COVID-related drug data.[14] An additional data sharing partnership with several other government institutes resulted in a study detailing the COVID-related risks for patients with chronic obstructive pulmonary disease.[15][16]

See also

References

  1. ↑ Wadman, Meredith (12 January 2012). "US translational-science centre gets under way". Nature 481 (7380): 128. doi:10.1038/481128a. PMID 22237088. Bibcode: 2012Natur.481..128W. 
  2. ↑ "Budget". 12 March 2015. https://ncats.nih.gov/about/center/budget. 
  3. ↑ "Authorization". http://www.ncats.nih.gov/about/budget/authorization.html. 
  4. ↑ Wadman, Meredith (12 January 2012). "US translational-science centre gets under way". Nature 481 (7380): 128. doi:10.1038/481128a. PMID 22237088. Bibcode: 2012Natur.481..128W. 
  5. ↑ "NIH's Cures Acceleration Network (CAN) – Rare Disease Legislative Advocates". 12 May 2010. http://rareadvocates.org/nihs-cures-acceleration-network-can/. 
  6. ↑ "Cures Acceleration Network (CAN) Review Board – National Center for Advancing Translational Sciences". 13 March 2015. http://www.ncats.nih.gov/advisory/canboard. 
  7. ↑ "NCATS Directors". https://www.nih.gov/about-nih/what-we-do/nih-almanac/national-center-advancing-translational-sciences-ncats. 
  8. ↑ 8.0 8.1 "Divisions & Offices". 12 March 2015. https://ncats.nih.gov/about/center/org. 
  9. ↑ "About NCATS" (in en). 2017-10-30. https://ncats.nih.gov/about. 
  10. ↑ Sacks, Leonard V.; Shamsuddin, Hala H.; Yasinskaya, Yuliya I.; Bouri, Khaled; Lanthier, Michael L.; Sherman, Rachel E. (2014-01-22). "Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000–2012". JAMA 311 (4): 378–384. doi:10.1001/jama.2013.282542. ISSN 0098-7484. PMID 24449316. 
  11. ↑ "NCATS Programs & Initiatives" (in en). 2015-03-16. https://ncats.nih.gov/programs. 
  12. ↑ "NCATS Programs & Initiatives" (in en). 2015-03-16. https://ncats.nih.gov/programs. 
  13. ↑ "Issues in Translation" (in en). 2015-03-12. https://ncats.nih.gov/translation/issues. 
  14. ↑ "COVID-19 OpenData Portal" (in en). 2020-06-08. https://ncats.nih.gov/expertise/covid19-open-data-portal. 
  15. ↑ "N3C Data Reveals COVID-19's Stark Mortality Risk in People with COPD" (in en). 2021-09-23. https://ncats.nih.gov/pubs/features/national-ehr-data-resource-reveals-covid-19-stark-mortality-risk-in-people-with-copd. 
  16. ↑ Meza, Daniel; Khuder, Basil; Bailey, Joseph I; Rosenberg, Sharon R; Kalhan, Ravi; Reyfman, Paul A (August 2021). "Mortality from COVID-19 in Patients with COPD: A US Study in the N3C Data Enclave". International Journal of Chronic Obstructive Pulmonary Disease 16: 2323–2326. doi:10.2147/copd.s318000. ISSN 1178-2005. PMID 34413640. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Organization:National_Center_for_Advancing_Translational_Sciences&oldid=3398124"